Drug Profile
Research programme: cancer therapeutics - Merck/Piramal Healthcare
Alternative Names: Cancer therapeutics - Merck/Piramal Healthcare; TargetYLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Merck & Co; Piramal Life Sciences
- Developer Merck & Co; Piramal Enterprises
- Class Small molecules
- Mechanism of Action Insulin-like growth factor-I receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in India
- 15 Jun 2012 Preclinical trials in Cancer in India (unspecified route)